Androgen Receptor Expression in Estrogen Receptor Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations
|
|
- Horace O’Brien’
- 6 years ago
- Views:
Transcription
1 Anatomic Pathology / ANDROGEN RECEPTOR IN BREAST CANCER Androgen Receptor Expression in Estrogen Receptor Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations S. Nicholas Agoff, MD, 1 Paul E. Swanson, MD, 1 Hannah Linden, MD, 2 Stephen E. Hawes, PhD, 3 and Thomas J. Lawton, MD 1 Key Words: Androgen receptor; Breast cancer; Estrogen receptor negative Abstract We sought to determine the prevalence of androgen receptor (AR) expression in a predominantly estrogen receptor (ER)-negative subset of breast cancers and delineate the immunohistochemical and clinical associations, including whether AR expression has prognostic significance in ER-negative tumors. We identified 69 ER-negative and 19 ER-positive breast cancer cases with concurrent immunohistochemical prognostic panels (ER, PR, HER-2/neu, Ki-67, and p53); immunohistochemical analysis was performed for AR using standard techniques. Clinical data were extracted from medical records. χ 2 tests were used to assess associations between variables. AR was found in 49% (34/69) of ER-negative and 89% (17/19) of ERpositive cases. In ER-negative tumors, AR was associated with increased age (P =.02), postmenopausal status (P <.001), tumor grade (P =.03), tumor size (P =.03), and HER-2/neu overexpression (P =.003). In ER-positive tumors, AR was associated with progesterone receptor expression (P <.03). In univariate analysis of ER-negative tumors, patients with AR-positive tumors had significantly better disease-free survival (P =.049). AR is expressed in a significant number of ER-negative cases and shows significant associations with important clinical and pathologic prognostic factors. The role of hormone receptors as prognostic and therapeutic tools has widespread acceptance in the management of breast cancer. The expression of estrogen receptor (ER), in particular, is thought to be of great importance, predicting an approximately 50% to 75% response rate to hormonal therapy, while ER-negative tumors have a less than 10% chance of response. 1,2 ER positivity also is prognostic of delayed recurrence in primary breast cancer. 3 The data concerning progesterone receptor (PR) are not as clear, but ER-negative tumors with PR are thought to have an intermediate response rate compared with ER- and PR-positive tumors. 2 In addition, estrogen is thought to play a major role in the development and progression of breast cancer. 4 Androgens also are thought to have an important role in breast cancer. The risk of breast cancer is increased in postmenopausal women with high estrogen levels as well as in women with high androgen levels. 5,6 The mechanism by which androgens contribute to breast cancer is not well understood, but studies have shown that androgens can induce proliferative changes in breast tissue, and animal models have shown that administration of both estrogen and androgens can induce tumor formation. 7,8 Also, recent studies have shown that the breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor (AR). 9 Studies of AR expression in breast cancer have shown that AR is expressed in the majority of ER-positive tumors; however, these studies have not emphasized the expression of AR in ER-negative tumors; most had a majority of ER-positive tumors In addition, while some of these studies found that expression of AR predicted response to hormonal therapy and overall survival, they also showed that AR status was not predictive of disease-free survival in patients with ER-positive Am J Clin Pathol 2003;120:
2 Agoff et al / ANDROGEN RECEPTOR IN BREAST CANCER tumors. In these studies, ER status, not AR status, was an independent prognostic factor for disease-free survival The purposes of the present study were to analyze expression of AR in paraffin-fixed tissues in a subset of patients from a university hospital with predominantly ERnegative tumors and to correlate AR expression with other prognostic variables as well as clinicopathologic data, including disease-free survival. Materials and Methods During the period July 1990 to July 2002, ER-negative (n = 69) and ER-positive (n = 19) breast cancer cases with concurrent immunohistochemical prognostic panels (ER, PR, HER-2/neu, Ki-67, and p53) were randomly selected from the files of the Department of Pathology, University of Washington Medical Center, Seattle. Approval was obtained for this study from the University of Washington Medical Center Human Subjects division (application E01). The following information was obtained from all patient s medical records (when available): age, menopausal status, grade and type of tumor, tumor size, lymph node status, clinical stage, family history of breast and ovarian cancer, BRCA mutation, pregnancy, and clinical follow-up data. Tumors were graded according to the modified Scarff- Bloom-Richardson system. 15 Staging followed the current American Joint Committee on Cancer staging criteria. 16 All patients with primary breast carcinoma received current standard therapy: lumpectomy and radiation or modified radical mastectomy; sentinel node biopsy (and axillary dissection if the sentinel node was positive); or axillary dissection, with radiation therapy for tumors with extensive axillary involvement (>5 cm primary tumor) or with close margins. Chemotherapy and hormone therapy treatments were based on characteristics of the tumor and patient preferences. In general, patients with ER-negative, Her2-neu positive or multiply node-positive tumors received anthracycline-based therapy, whereas patients with more favorable prognostic characteristics were treated with a modified Cooper-type regimen of cyclophosphamide (Cytoxan), methotrexate, 5-fluorouracil (CMF) weekly therapy. Only patients with hormone receptor positive tumors received hormonal therapy. Immunohistochemical Analysis ER, PR, AR, Ki-67, and p53 Antibodies, vendor sources, working dilutions, and tissue pretreatments are listed in Table 1. Antigen localization was performed with a modified avidin-biotin (ABC) immunoperoxidase method according to standard protocols (Vector Laboratories, Burlingame, CA). 3,3'-diaminobenzidine was used as the chromogen. The immunostaining results for ER, PR, and AR were assessed semiquantitatively and reported as positive if more than 5% of cells immunostained in a tumor. Ki-67 expression was graded semiquantitatively as low (<10%), intermediate (10%-20%), or high (>20%). 17 p53 overexpression was defined as more than 50% of the cells with strong nuclear staining. 18 Her-2/neu Immunohistochemical analysis for Her-2/neu was performed using a polyclonal antibody to the Her-2/neu protein (Table 1). Four-micrometer sections were deparaffinized and rehydrated in graded alcohols. For each case, 1 slide was subjected to pretreatment (Table 1) and the other was not. Slides then were incubated with the anti HER- 2/neu antibody, which is the same currently available in the HercepTest kit (DAKO, Carpinteria, CA), except it is not in the prediluted form. For positive controls, breast carcinomas known to be immunoreactive for HER-2/neu with fluorescent in situ hybridization (FISH)-proven gene amplification were used. Benign breast tissue in the background provided the internal negative control. FISH for HER-2/neu Gene Amplification For an intermediate HER-2/neu immunohistochemical result (9 cases), FISH was performed as specified by the Table 1 Antibodies and Dilutions Used Antibody to Clone Vendor * Pretreatment Working Dilution Estrogen receptor 1D5 AMAC 18 min microwave in 10-mmol/L citrate concentration, ph 6.0 1:1,000 Progesterone receptor PR88 BioGenex 18 min microwave in 10-mmol/L citrate concentration, ph 6.0 1:500 Androgen receptor F BioGenex 15 min microwave in 0.5-mol/L tris(hydroxymethyl)aminomethane 1:500 concentration, ph 10 Her-2/neu Polyclonal DakoCytomation A, no pretreatment; B, 15 min microwave in 10-mmol/L citrate A, 1:1,000; concentration, ph 6.0 B, 1:2,000 Ki-67 MIB-1 DakoCytomation 18 min microwave in 10-mmol/L citrate concentration, ph 6.0 1:500 p53 DO7 DakoCytomation 15 min microwave in 10-mmol/L citrate concentration, ph 6.0 1:1,000 * AMAC (Immunotech International), Westbrook, ME; BioGenex, San Ramon, CA; DakoCytomation, Carpinteria, CA. 726 Am J Clin Pathol 2003;120: Downloaded 726 from
3 Anatomic Pathology / ORIGINAL ARTICLE manufacturer using the PathVysion HER-2 DNA Probe Kit (Vysis, Downers Grove, IL). Briefly, 4- to 5-µm tissue sections were baked for 20 minutes at 60 C, deparaffinized in two 10-minute changes of xylene, transferred through two 5-minute changes of 100% ethanol, and air dried. The slides then were pretreated, digested in protease solution, fixed, denatured, and hybridized as specified by the manufacturer. FISH slides were scored according to the manufacturer s guidelines. Statistics Univariate χ 2 tests were used to assess associations between patient and tumor characteristics and AR positivity. Mantel-Haenszel tests for trend were used to measure associations in ordered categorical factors, such as tumor grade and size and clinical stage. Cox proportional hazards modeling was applied for analyses regarding time to disease recurrence, using likelihood ratio tests to assess differences by AR positivity. Kaplan-Meier actuarial methods were used to calculate disease-free survival probabilities. Results Patient and Tumor Characteristics Patient and tumor characteristics are summarized in Table 2. The patients ranged in age from 26 to 91 years (mean, 54.9 years); 31 (35%) of 88 patients were younger than 50 years of age, and 37 (42%) were premenopausal. Of the cases, 84 were biopsy specimens of primary breast carcinomas, and 4 were biopsy specimens of metastatic disease. The majority of tumors were ductal carcinomas (n = 75), with a few lobular (n = 7) and pleomorphic lobular carcinomas (n = 4). Most tumors (58/86 [67%]) were high grade, and slightly more than half of the primary tumors had lymph node metastasis at diagnosis (43/76 [57%]). In 2 metastatic tumors, the type and grade were not specified. In ER-negative tumors, AR positivity Image 1 was associated with increasing age (P =.02), postmenopausal status (P <.001), lower tumor grade (P =.03), smaller tumor (P =.03), and Her-2/neu overexpression (P =.003). Lack of AR expression showed a trend toward association with high Ki-67 expression and with pregnancy (only 1 of 6 pregnant women had tumors that were AR-positive), but these trends were not statistically significant (P =.06 and.10, respectively). In ER-positive tumors, AR positivity was associated with PR positivity (P =.03) and showed a trend toward association with lack of Her-2/neu overexpression, although this was not statistically significant (P =.06). There were no other associations with AR positivity in ER-positive tumors; however the number of ER-positive cases was small, and nearly all were positive for AR. The presence of AR strongly correlated with estrogen positivity: 17 (89%) of 19 ER-positive breast cancers were positive for AR compared with only 34 (49%) of 69 ERnegative breast tumors (P =.002). Samples from only 2 patients with proven BRCA1 mutations were included in the study, and both of those tumors were negative for ER and AR. There was no significant correlation between AR and family history of breast or ovarian cancer. Follow-up for Disease Recurrence Follow-up for disease recurrence was complete for 66 women (75%), including 57 of 69 women with ER-negative tumors (83%). Follow-up after treatment ranged from 4 to 120 months, with a mean follow-up of 25 months. Followup data are summarized in Table 3. During this time, 21 (84%) of 25 patients with ER-negative, AR-positive tumors remained disease free, while only 17 (53%) of 32 women with ER-negative, AR-negative tumors were disease free. Of 57 women with ER-negative tumors, 19 (33%) experienced disease relapse: 15 (47%) of 32 with AR-negative tumors but only 4 (16%) of 25 with AR-positive tumors (Table 3). None of the women with ER-negative, AR-positive tumors died of disease, but 4 with ER-negative, ARnegative tumors died of disease. The follow-up data for women with ER-positive tumors were too scant (9 of 19 patients) to draw meaningful conclusions. In univariate Cox regression analysis of disease-free survival in patients with ER-negative tumors, patients with tumors that were AR-positive had only 33% the risk of recurrence compared with that for patients with AR-negative tumors (P =.049; hazard ratio, 0.33; 95% confidence interval, ) Table 4 and Figure 1. Other factors that showed a significant association with poor prognosis in ER-negative tumors in univariate analyses included age younger than 50 years, 4 or more positive lymph nodes, tumor larger than 5 cm, high level of Ki-67 expression, and stage III tumors. The other factors (age 60 years or older, Her-2/neu status, grade, PR status [data not shown], pregnancy, family history, p53, ductal histologic features [data not shown], and menopausal status) were not significantly associated (P.2) with a poor prognosis in ERnegative tumors. In multivariate analysis, adjusted hazard ratios for AR expression were not significant (P =.5) when adjusting for age, tumor size, positive nodes, clinical stage, and Ki-67 expression. However, those factors also lost significance in multivariate analysis (P.5), except for Ki-67 expression (hazard ratio, 8.7; P =.02). Am J Clin Pathol 2003;120:
4 Agoff et al / ANDROGEN RECEPTOR IN BREAST CANCER Table 2 Patient and Tumor Characteristics Associated With ER and AR Status * ER Tumors (n = 69) ER+ tumors (n=19) Characteristic AR (n = 35) AR+ (n = 34 [49%]) P AR (n = 2) AR+ (n = 17 [89%]) P Age (y).02.4 < (29) 0 2 (100) (31) 0 6 (100) (59) 1 1 (50) (33) 0 4 (100) (100) 1 4 (80) Menopausal status < Premenopausal 22 7 (24) 0 8 (100) Postmenopausal (69) 2 9 (82) Tumor grade.03.9 I 1 1 (50) 1 8 (89) II 3 11 (79) 0 3 (100) III (39) 1 6 (86) Tumor type.5.2 Ductal (47) 2 9 (82) Lobular 1 2 (67) 0 4 (100) Pleomorphic lobular (100) Tumor size (cm) (67) 1 9 (90) > (35) 1 6 (86) >5 4 2 (33) 0 0 Lymph nodes.9.3 Negative (45) 2 9 (82) Positive (45) 0 5 (100) Clinical stage.4.9 I 4 6 (60) 0 5 (100) II (53) 2 8 (80) III 11 4 (27) 0 3 (100) IV 5 6 (55) 0 1 (100) Progesterone receptor.3.03 Negative (50) 2 4 (67) Positive (100) Her-2/neu Negative (38) 1 16 (94) Positive 3 13 (81) 1 1 (50) Ki-67 expression.06.8 Low 2 6 (75) 1 4 (80) Intermediate 3 6 (67) 0 5 (100) High (43) 1 7 (88) p Negative (58) 2 14 (88) Positive (44) 0 2 (100) Pregnant.10 No (52) 2 16 (89) Yes 5 1 (17) 0 0 Family history No (50) (87).8 Yes 9 5 (36) 0 4 (100) AR, androgen receptor; ER, estrogen receptor. * Data for AR+ tumors are given as number (percentage of the row total for ER tumors or ER+ tumors). Data were not available for all cases for some characteristics. Modified Scarff-Bloom-Richardson grading system. 15 At least 1 first-degree relative with breast and/or ovarian cancer. Discussion The prognostic significance of ER and PR expression in breast cancer and their roles in therapy are well recognized, but the significance of AR expression is less well characterized. Previous studies have focused on ER-positive tumors and have shown some association between AR status and disease-free survival, as well as response to endocrine therapy, but these findings are obscured by the presence of ER Our study focused on ER-negative tumors, since most ER-positive tumors are AR-positive, and ER-negative tumors characteristically have a poorer prognosis and are thought to respond poorly to endocrine therapy. 1 We found that AR expression correlated with longer survival in a cohort of women with ER-negative tumors. In one of the largest studies of AR status in breast cancer (1,371 patients), Bryan and colleagues 11 found a highly significant association between AR status and survival (P <.001) that remained significant even when taking ER status into account. In addition, they found that AR positivity influenced the response of the primary tumor and metastasis to tamoxifen therapy. Unfortunately, they did not assess the response to hormonal therapy in any ER-negative, AR-positive tumors. In a more recent study of Am J Clin Pathol 2003;120: Downloaded 728 from
5 Anatomic Pathology / ORIGINAL ARTICLE A B C Image 1 Androgen receptor (AR) expression in an estrogen receptor (ER)-negative tumor (A, H&E; B, ER; C, AR; 40). patients, Kuenen-Boumeester and colleagues 12 showed that while AR status was a significant prognostic factor for disease-free survival in univariate analysis, in multivariate analysis, only lymph node status, tumor size, and ER status were independent prognostic variables. The findings in our study are in accord with previous studies in that we found that AR expression was associated significantly with disease-free survival in univariate analysis. However, unlike previous analyses, our study focused on ERnegative tumors and found an association between AR expression and survival in this subset of patients, who characteristically have a worse prognosis than patients with ERpositive tumors. Whether this difference in disease-free survival is indicative of a more indolent nature of AR-positive tumors or whether it reflects sensitivity to treatment is unclear, but none of these patients received antiestrogen or antiandrogen therapy. In multivariate analysis, the association between AR status and survival did not maintain significance; however, neither did other factors such as tumor size, lymph node status, and clinical stage. This implies that owing to the small data set, the statistical power was lacking to detect significant differences after adjusting for other important factors. Other authors have found significant associations between AR status and prognostic factors as well. Isola 14 found a significant correlation between AR status and tumor grade, similar to our findings, but did not find a positive correlation between AR status and HER-2/neu status, which was present in our study. Also, unlike the findings of Kuenen-Boumeester et al, 12 we did not find a significant correlation between AR status and Ki-67 expression, although there was a trend toward an association. Bryan and colleagues 11 did not find a significant correlation between Am J Clin Pathol 2003;120:
6 Agoff et al / ANDROGEN RECEPTOR IN BREAST CANCER Table 3 Follow-up Information on Patients According to Receptor Status * Receptor Status No Evidence of Disease Alive With Disease Died of Disease ER AR+ (n = 25) 21 (84) 4 (16) 0 (0) ER AR (n = 32) 17 (53) 11 (34) 4 (13) ER+ AR+ (n = 8) 6 (75) 1 (13) 1 (13) ER+ AR (n = 1) 0 (0) 1 (100) 0 (0) Total (n = 66) 44 (67) 17 (26) 5 (8) AR, androgen receptor; ER, estrogen receptor. * Data are given as number (percentage). AR and menopausal status in their patients; however, we found that AR expression not only correlated with increasing age, but also was highly significantly correlated with menopausal status. Some of these differences may be Table 4 Univariate Analysis of Factors Associated With Poor Prognosis in Patients With ER-Negative Tumors Hazard Ratio Characteristic (95% Confidence Interval) * P Age (y) < ( ) (ref) ( ).09 Androgen receptor Positive 0.33 ( ).05 Tumor size (cm) (ref) > ( ).08 >5 8.4 ( ).02 Lymph nodes ( ) ( ).01 Clinical stage I or II 1.0 (ref) III 3.6 ( ).02 IV 1.9 ( ).3 Ki-67 expression Low or intermediate 1.0 (ref) High 5.4 ( ).03 Tumor grade 15 I or II 1.0 (ref) III 2.3 ( ).2 Her-2/neu Positive 0.55 ( ).3 p53 Positive 1.8 ( ).4 Pregnant No 1.0 (ref) Yes 1.9 ( ).4 Menopausal status Premenopausal 1.0 (ref) Postmenopausal 0.64 ( ).8 Family history No 1.0 (ref) Yes 2.0 ( ).2 ref, reference value. * From Cox proportional hazards regression analysis. explained by the fact that our study emphasized ER-negative tumors, which tend to be high-grade ductal carcinomas with more advanced stage at diagnosis. Although the functional role of androgens in breast cancer is uncertain, epidemiologic associations and animal models implicate androgens in breast carcinogenesis. The incidence of breast cancer is high in postmenopausal women when androgenic levels are high, and the risk of breast cancer is increased in women with high estrogen levels and in those with high androgen levels. 5,6,19 Wong and Xie 7 and Xie and colleagues 8 have shown in animal models that testosterone in combination with estrogen can induce a high incidence of mammary carcinoma and that administration of flutamide can block changes induced by androgens. Similarly, Boccuzzi et al 20 showed that flutamide inhibited growth of rat mammary tumors. A major strength and distinguishing feature of our study is that it concentrates on ER-negative breast cancers, a group of tumors that have a poorer prognosis than ER-positive tumors; our data show that AR status can separate ER-negative tumors into more and less favorable prognostic groups. Because we chose to focus our study on this group of tumors, it included a preponderance of ER-negative, high-grade ductal carcinomas, as these features tend to be associated. Survival Distribution Function Disease-Free Survival (months) Figure 1 Disease-free survival curve for patients with estrogen receptor negative tumors stratified according to androgen receptor (AR) positivity (P =.049). Solid line, ARnegative; hatched line, AR-positive. 730 Am J Clin Pathol 2003;120: Downloaded 730 from
7 Anatomic Pathology / ORIGINAL ARTICLE Thus, we have less information regarding low-grade ERnegative tumors and about ER-negative, PR-positive tumors. This study was retrospective, so treatment was not influenced by AR expression. Because all patients received current standard therapies, treatment differed depending on the tumor, and our survival curves may reflect treatment sensitivity and the innate characteristics of the tumor. AR is expressed in almost 50% of ER-negative tumors, has significant associations with clinical, pathologic, and immunohistochemical prognostic factors, and is a predictor of disease-free survival in univariate analysis. Although statistical significance was lacking in our multivariate analysis, a larger sample and additional research may help clarify whether AR status is a significant independent prognostic factor. While the functional role of AR in breast cancer remains unclear, further exploration of this area could expand the repertoire of potential treatments for patients with ER-negative breast cancers. From the Departments of 1 Pathology, 2 Oncology, and 3 Epidemiology, University of Washington, Seattle. Supported in part by a generous gift from the Avon Foundation, New York, NY (Dr Linden). Address reprint requests to Dr Agoff: Assistant Professor, Pathology and Cytopathology, UWMC/Harborview Medical Center, Box , 1959 NE Pacific St, Seattle, WA References 1. Wittliff JL. Steroid-hormone receptors in breast cancer. Cancer. 1984;53: Osborne CK, Yochmowitz MG, Knight WA, et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46: Knight WA, Livingston RB, Gregory EJ, et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977;37: Vessey MP. Effect of endogenous and exogenous hormones on breast cancer: epidemiology. Verh Dtsch Ges Pathol. 1997;81: Cauley JA, Lucas FL, Kuller LH, et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer: study of Osteoporotic Fractures Research Group. Ann Intern Med. 1999;130: Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90: Wong YC, Xie B. The role of androgens in mammary carcinogenesis. Ital J Anat Embryol. 2001;106: Xie B, Tsao SW, Wong YC. Sex hormone induced mammary carcinogenesis in female noble rats: the role of androgens. Carcinogenesis. 1999;20: Park JJ, Irvine RA, Buchanan G, et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res. 2000;60: Brys M, Wojcik M, Romanowicz-Makowska H, et al. Androgen receptor status in female breast cancer: RT-PCR and Western blot studies. J Cancer Res Clin Oncol. 2002;128: Bryan RM, Mercer RJ, Bennett RC, et al. Androgen receptors in breast cancer. Cancer. 1984;54: Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer. 1996;32A: Soreide JA, Lea OA, Varhaug JE, et al. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol. 1992;18: Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol. 1993;170: Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19: Greene FL, Page DL, Fritz A, et al, eds. The AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002: Brown RW, Allred CD, Clark GM, et al. Prognostic value of Ki-67 compared to S-phase fraction in axillary node negative breast cancer. Clin Cancer Res. 1996;2: Barnes DM, Dublin EA, Fisher CJ, et al. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol. 1993;24: Secreto G, Toniolo P, Berrino F, et al. Increased androgenic activity and breast cancer risk in premenopausal women. Cancer Res. 1984;44: Boccuzzi G, Tamagno E, Brignardello E, et al. Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide. J Cancer Res Clin Oncol. 1995;121: Am J Clin Pathol 2003;120:
Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationExpression of androgen receptors in primary breast cancer
Annals of Oncology 21: 488 492, 2010 doi:10.1093/annonc/mdp510 Published online 3 November 2009 Expression of androgen receptors in primary breast cancer S. Park 1, J. Koo 2, H. S. Park 1, J.-H. Kim 1,
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationARTICLES. erbb-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
ARTICLES erbb-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer Ann D. Thor, Donald A. Berry, Daniel R. Budman, Hyman B. Muss, Timothy Kute, I. Craig Henderson, Maurice Barcos,
More informationHormone receptor and Her2 neu (Her2) analysis
ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional
More informationW omen under 35 years of age form only a small
323 ORIGINAL ARTICLE Immunohistochemical prognostic index for breast cancer in young women I Guerra, J Algorta, R Díaz de Otazu, A Pelayo, J Fariña... See end of article for authors affiliations... Correspondence
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationEstrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
Journal of Bangladesh College of Physicians and Surgeons Vol. 28, No. 3, September 2010 Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
More informationequally be selected on the basis of RE status of the primary tumour. These initial studies measured RE
Br. J. Cancer (1981) 43, 67 SOLUBLE AND NUCLEAR OESTROGEN RECEPTOR STATUS IN HUMAN BREAST CANCER IN RELATION TO PROGNOSIS R. E. LEAKE*, L. LAING*, C. McARDLEt AND D. C. SMITH$ From the *Department of Biochemistry,
More informationNeuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters
& 2004 USCAP, Inc All rights reserved 0893-3952/04 $25.00 www.modernpathology.org Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical
More informationDOCTORAL THESIS SUMMARY
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA FACULTY OF MEDICINE DOCTORAL THESIS SUMMARY CLINICO-IMAGING STUDY OF INVASIVE DUCTAL BREAST CARCINOMAS CORRELATED TO HORMONAL RECEPTORS AND HER2/NEU ONCOPROTEIN
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 36 DECEMBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
More informationSupplementary Fig. 1: ATM is phosphorylated in HER2 breast cancer cell lines. (A) ATM is phosphorylated in SKBR3 cells depending on ATM and HER2
Supplementary Fig. 1: ATM is phosphorylated in HER2 breast cancer cell lines. (A) ATM is phosphorylated in SKBR3 cells depending on ATM and HER2 activity. Upper panel: Representative histograms for FACS
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationMy Personalized Breast Cancer Worksheet
My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationBREAST CANCER BREAST CANCER
BREAST CANCER George Raptis, M.D., M.B.A Division of Medical Oncology & Hematology College of Physicians & Surgeons Columbia University BREAST CANCER Epidemiology - Commonest cancer in women - About 235,000
More informationIs adjuvant chemotherapy necessary for Luminal A-like breast cancer?
JBUON 2018; 23(4): 877-882 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?
More informationA Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer
Elmer ress Original Article World J Oncol. 2017;8(3):71-75 A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer Hui Hu a, Wei Wei a, Xin Yi a, Ling Xin
More informationA comparison of Ki 67 proliferative index in primary tumor and axillary metastatic lymph nodes with length of survival in patients with breast cancer
DOI: 10.4149/BLL_2013_138 Bratisl Lek Listy 2013; 114 (11) CLINICAL STUDY A comparison of Ki 67 proliferative index in primary tumor and axillary metastatic lymph nodes with length of survival in patients
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationOutcomes of patients with inflammatory breast cancer treated by breast-conserving surgery
Breast Cancer Res Treat (2016) 160:387 391 DOI 10.1007/s10549-016-4017-3 EDITORIAL Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika Brzezinska 1 Linda J.
More informationClinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationKi67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
ARTICLE Ki67 Index, HER2 Status, and Prognosis of Patients With Breast Cancer Maggie C. U. Cheang, Stephen K. Chia, David Voduc, Dongxia Gao, Samuel Leung, Jacqueline Snider, Mark Watson, Sherri Davies,
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationClinico-pathological significance of extra-nodal spread in special types of breast cancer
Cancer Biol Med 2014;11:116-122. doi: 10.7497/j.issn.2095-3941.2014.02.006 ORIGINAL ARTICLE Clinico-pathological significance of extra-nodal spread in special types of breast cancer Ecmel Isik Kaygusuz,
More informationHER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade
Anatomic Pathology / HER2/NEU AMPLIFICATION IN BREAST CANCER HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade Elise R. Hoff, MD, Raymond R. Tubbs, DO, Jonathan L. Myles, MD,
More informationTreatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy
Treatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy Kyoung Ju Kim 1, Seung Jae Huh 1, Jung-Hyun Yang 2, Won Park 1, Seok Jin Nam
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationResearch Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
SAGE-Hindawi Access to Research International Breast Cancer Volume 20, Article ID 47957, 4 pages doi:0.406/20/47957 Research Article Stromal Expression of CD0 in Invasive Breast Carcinoma and Its Correlation
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationClinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer
Original Articles Jpn J Clin Oncol 2012;42(6)471 476 doi:10.1093/jjco/hys046 Advance Access Publication 3 April 2012 Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer Junnan Li,
More informationRESEARCH ARTICLE. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India
APJCP.2016.17.6.2995 RESEARCH ARTICLE Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India Dinesh Chandra Doval 1,2 *, P Suresh 1, Rupal Sinha 2, Saud Azam 2, Ullas Batra
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationModified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast
British Journal of Cancer (2011) 105, 698 708 All rights reserved 0007 0920/11 www.bjcancer.com Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationCorrelation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients
1568 Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients LIYING GUO 1, YU ZHANG 2, WEI ZHANG 3 and DILIMINA YILAMU 1 1 Department of
More informationCarcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
More informationCombined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement.
Combined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement. Ung O, Langlands A, Barraclough B, Boyages J. J Clin Oncology 13(2) : 435-443, Feb 1995 STUDY DESIGN
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationISPUB.COM. C Choccalingam, L Rao INTRODUCTION ESTROGEN AND PROGESTERONE RECEPTORS
ISPUB.COM The Internet Journal of Pathology Volume 13 Number 1 Learning Experience In Immunohistochemical Reporting Of Breast Cancer At A Rural Tertiary Hospital In India: A Comparison In Initial And Reviewed
More informationHER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer
Original article Annals of Oncology 13: 1398 1403, 2002 DOI: 10.1093/annonc/mdf217 HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer
More informationMiddle East Journal of Cancer; July 2015; 6(3):
Original Article Middle East Journal of Cancer; July 2015; 6(3): 143-150 A Survey of the Relationship between Serum Testosterone Level and Expressions of Androgen, Progesterone and Estrogen Receptors and
More informationPrognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer
Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationTumour markers in breast carcinoma correlate with grade rather than with invasiveness
doi: 10.1054/ bjoc.2001.1995, available online at http://www.idealibrary.com on http://www.bjcancer.com Tumour markers in breast carcinoma correlate with grade rather than with invasiveness F Wärnberg
More informationSection: Genetic Testing Last Reviewed Date: March Policy No: 42 Effective Date: June 1, 2014
Medical Policy Manual Topic: Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer Date of Origin: October 5, 2004 Section: Genetic Testing Last
More informationSCIENCE CHINA Life Sciences
SCIENCE CHINA Life Sciences RESEARCH PAPER April 2013 Vol.56 No.4: 335 340 doi: 10.1007/s11427-013-4435-y Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective
More informationOverview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 2010
Original Article Overview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 21 * DMRT clinical oncology, MSc. pathology. Summary:
More informationHer-2/neu expression and its correlation with ER status and various clinicopathological parameters
Original Research Article DOI: 10.5958/2394-6792.2016.00106.X Her-2/neu expression and its correlation with ER status and various clinicopathological parameters Kriti Chauhan 1,*, Monika Garg 2, Abhimanyu
More informationDetermination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined?
Anatomic Pathology / FISH f o r HER2: Wh e n to Use Ch r o m o s o m e 17 Determination of HER2 Amplification by In Situ Hybridization When Should Chromosome 17 Also Be Determined? John M.S. Bartlett,
More informationHypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients
Journal of BUON 17: 663-668, 2012 2012 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor
More informationReal-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1 3 positive lymph nodes: a retrospective study
Journal of Radiation Research, 2014, 55, 121 128 doi: 10.1093/jrr/rrt084 Advance Access Publication 20 June 2013 Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1 3 positive
More informationMinimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies
Original article Annals of Oncology 15: 1633 1639, 2004 doi:10.1093/annonc/mdh434 Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies
More informationRace is not a factor in overall survival in patients with triple negative breast cancer: a retrospective review
Starlard-Davenport et al. SpringerPlus 2013, 2:516 a SpringerOpen Journal RESEARCH Open Access Race is not a factor in overall survival in patients with triple negative breast cancer: a retrospective review
More informationRESEARCH COMMUNICATION. High Ki-67 Expression is a Poor Prognostic Indicator of 5-Year Survival in Patients with Invasive Breast Cancer
RESEARCH COMMUNICATION High Ki-67 Expression is a Poor Prognostic Indicator of 5-Year Survival in Patients with Invasive Breast Cancer Xue-Qin Yang 1,2, Fu-Bing Wang 1, Chuang Chen 1, Chun-Wei Peng 1,
More informationAdjuvan Chemotherapy in Breast Cancer
Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality
More informationLow ER+ Breast Cancer. Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD ABSTRACT
Low ER+ Breast Cancer Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD From the Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA.
More informationNEUROENDOCRINE DIFFERENTIATED BREAST CARCINOMA
+ NEUROENDOCRINE DIFFERENTIATED BREAST CARCINOMA + INTRODUCTION + NEUROENDOCRINE FEATURES IN BREAST CARCINOMA Incidence of 2-5% Seen in various histopathological types of breast carcinoma Seen in both
More informationEvaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
More informationDoes HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey
MYERS et al. ORIGINAL ARTICLE Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey J.A. Myers MD FRCPC, G.
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationKey Words: Cytology, Grading, Breast Carcinoma
BREAST CARCINOMA ASPIRATES: A STUDY ON CYTOLOGICAL GRADING *Subhashish Das, Kalyani and Harendra Kumar Department of Pathology; Sri Devaraj Urs Medical College, Tamaka, Kolar *Author for Correspondence
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationCase Scenario 1 History and Physical 3/15/13 Imaging Pathology
Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts
More informationRESEARCH ARTICLE. Wan Faiziah Wan Abdul Rahman 1 *, Mohd Hashairi Fauzi 2, Hasnan Jaafar 1. Abstract. Introduction
RESEARCH ARTICLE Expression of DNA Methylation Marker of Paired-Like Homeodomain Transcription Factor 2 and Growth Receptors in Invasive Ductal Carcinoma of the Breast Wan Faiziah Wan Abdul Rahman 1 *,
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationClinical Policy Title: Breast cancer index genetic testing
Clinical Policy Title: Breast cancer index genetic testing Clinical Policy Number: 02.01.22 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2016
More informationProperties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.12.4921 Properties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up RESEARCH ARTICLE Properties of Synchronous Versus Metachronous
More informationARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW
doi:10.1016/j.ijrobp.2005.08.024 Int. J. Radiation Oncology Biol. Phys., Vol. xx, No. x, pp. xxx, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front matter
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast
Collecting Cancer Data Breast NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationRole of Genomic Profiling in (Minimally) Node Positive Breast Cancer
Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin
More information